Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. More Details
Undervalued with reasonable growth potential.
Share Price & News
How has Elos Medtech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ELOS B has not had significant price volatility in the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: ELOS B underperformed the Swedish Medical Equipment industry which returned 24% over the past year.
Return vs Market: ELOS B underperformed the Swedish Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Elos Medtech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StShould You Investigate Elos Medtech AB (publ) (STO:ELOS B) At kr85.00?
3 weeks ago | Simply Wall StReturns On Capital At Elos Medtech (STO:ELOS B) Paint An Interesting Picture
1 month ago | Simply Wall StThe Price Is Right For Elos Medtech AB (publ) (STO:ELOS B)
Is Elos Medtech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ELOS B (SEK85.6) is trading below our estimate of fair value (SEK206.59)
Significantly Below Fair Value: ELOS B is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ELOS B is good value based on its PE Ratio (23.9x) compared to the SE Medical Equipment industry average (38.4x).
PE vs Market: ELOS B is poor value based on its PE Ratio (23.9x) compared to the Swedish market (22.8x).
Price to Earnings Growth Ratio
PEG Ratio: ELOS B is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: ELOS B is good value based on its PB Ratio (1.2x) compared to the SE Medical Equipment industry average (5.3x).
How is Elos Medtech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELOS B's forecast earnings growth (27.4% per year) is above the savings rate (0.5%).
Earnings vs Market: ELOS B's earnings (27.4% per year) are forecast to grow faster than the Swedish market (13.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ELOS B's revenue (7.5% per year) is forecast to grow faster than the Swedish market (3% per year).
High Growth Revenue: ELOS B's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ELOS B's Return on Equity is forecast to be low in 3 years time (7.7%).
How has Elos Medtech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ELOS B has high quality earnings.
Growing Profit Margin: ELOS B's current net profit margins (4.9%) are higher than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: ELOS B's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: ELOS B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ELOS B had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (18.4%).
Return on Equity
High ROE: ELOS B's Return on Equity (5.2%) is considered low.
How is Elos Medtech's financial position?
Financial Position Analysis
Short Term Liabilities: ELOS B's short term assets (SEK325.4M) exceed its short term liabilities (SEK169.7M).
Long Term Liabilities: ELOS B's short term assets (SEK325.4M) exceed its long term liabilities (SEK323.6M).
Debt to Equity History and Analysis
Debt Level: ELOS B's debt to equity ratio (45.9%) is considered high.
Reducing Debt: Insufficient data to determine if ELOS B's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ELOS B's debt is well covered by operating cash flow (41.2%).
Interest Coverage: ELOS B's interest payments on its debt are not well covered by EBIT (2.8x coverage).
What is Elos Medtech current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ELOS B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ELOS B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ELOS B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELOS B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ELOS B is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ELOS B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan Wahlström (53 yo)
Mr. Jan Wahlström has been the Chief Executive Officer and President of Elos Medtech AB since July 1, 2016. Mr. Wahlström joined Elos Medtech from his role as President of Larodan AB. Mr. Wahlström served ...
|President & CEO||4.25yrs||no data||0.15% |
|Chief Financial Officer||1.33yrs||no data||0.051% |
|Marketing Director||no data||no data||0.0059% |
|QA/RA Quality Director||no data||no data||0.0012% |
|President of Forshemgruppen AB||17.75yrs||no data||no data|
|CEO of Elos Medtech Pinol A/S & Business Unit Director of Dental||no data||no data||2.98% |
|Chief Executive Officer of Elos Medtech Microplast AB||no data||no data||no data|
|CEO of Elos Medtech Onyx & Global Business Director of Orthopedics||no data||no data||no data|
|Chief Executive Officer of Elos Medtech Tianjin Co. Ltd||no data||no data||no data|
|Chief Executive Officer of Elos Medtech Timmersdala AB||no data||no data||no data|
Experienced Management: ELOS B's management team is considered experienced (4.3 years average tenure).
|Independent Chairman of the Board||3.75yrs||kr400.00k||0.29% |
|Independent Director||3.5yrs||kr235.00k||0.036% |
|Independent Director||8.75yrs||kr175.00k||0.049% |
|Independent Director||4.5yrs||kr175.00k||0.012% |
|Independent Director||1.75yrs||kr215.00k||0.011% |
|Independent Director||1.75yrs||kr175.00k||no data|
Experienced Board: ELOS B's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ELOS B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Elos Medtech AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Elos Medtech AB (publ)
- Ticker: ELOS B
- Exchange: OM
- Founded: 1923
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr679.326m
- Shares outstanding: 8.07m
- Website: https://www.elosmedtech.com
Number of Employees
- Elos Medtech AB (publ)
- Torsgatan 5B
- Västra Götaland County
- 411 04
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ELOS B||OM (OMX Nordic Exchange Stockholm)||Yes||Series B Shares||SE||SEK||May 1993|
|0IZX||LSE (London Stock Exchange)||Yes||Series B Shares||GB||SEK||May 1993|
|ELOSBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Series B Shares||GB||SEK||May 1993|
|EI9||DB (Deutsche Boerse AG)||Yes||Series B Shares||DE||EUR||May 1993|
|ELSB.F||OTCPK (Pink Sheets LLC)||Yes||Series B Shares||US||USD||May 1993|
Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. The company operates in three segments: Dental, Orthopedics, and Life Science. Its produ ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 22:13|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.